In the corporate venture studio model, the line between what the FI approves and what the studio decides is the whole product. The governance map in RACI.
Delegate execution, keep control. The operating model is the specific division of rights that lets you do both.
A Chief Risk Officer's first objection to a corporate venture studio is almost never cost or speed. It is control. "We can't let an external team make decisions for us." Fair concern, wrong read of the model, and worth correcting in full, because the correction is the most important thing a CVS actually sells.
The short version: the institution keeps strategic control and delegates operational control, and those two separate more cleanly than a risk officer expects. Split them well and you hold authority over everything that matters to you while shedding the operational burden that stalls internal efforts. Split them badly and you have rebuilt the exact structure that makes internal labs slow. So the operating model is not paperwork wrapped around the real work. The division of rights is the real work.
The split is simple enough to state on one page.
Your institution holds the approval rights, and they are the ones that should keep a risk officer up at night: the venture thesis, the sectors in play, the compliance bar, the brand, and the criteria that decide when a venture gets stopped. On a second tier you input where your knowledge genuinely beats the studio's, on product direction, customer introductions, and regulatory navigation. Everything else you simply stay informed on, sprint progress, financial metrics, team changes.
The studio takes the operational half. It decides team composition, product roadmap, technical architecture, and vendor selection, runs the actual work, the validation cycles, the build, customer acquisition, fundraising, and reports back through weekly dashboards, gate reviews, and quarterly updates. The shorthand: you own what gets built and why, the studio owns how and how fast.
Between those two sits a joint venture board, meeting on a fixed cadence, monthly being the common pattern for corporate studios. That board is where strategy and execution meet without either one swallowing the other.
Strategic control without operational burden is a specific division of rights, written down before anything is built. Treat it as a slogan and you will get the boundary wrong.
This part takes a minute to see. Internal labs do not stall for lack of talent. They stall because ventures inside a bank get pulled toward the org chart instead of the customer. It is a pattern anyone who has run corporate innovation will recognize: projects drift toward what the senior sponsor prefers rather than what the market is actually signaling. We unpacked that political gravity in detail elsewhere. Every project answers to a sponsor, a steering committee, and three budgets it happens to touch. So it drifts.
The operating model is the fix for exactly that. Execution lives outside the org chart, where political gravity has nothing to grip. The studio's product roadmap is not up for a vote in a steering committee, because the steering committee does not own it. At the same time, you have not handed over the things that genuinely should be yours: what gets built, in which sectors, under what compliance bar, and when to stop.
That is why the line cannot be fuzzy. If the institution gets approval rights over execution, the venture is back inside the org chart and the whole advantage is gone. If the studio gets approval rights over thesis or compliance, the institution has handed a regulated, brand-bearing decision to an outside party, which no CRO will accept and no CRO should. The value is created precisely at the boundary, and only if the boundary is sharp.
A governance map is easy to write and hard to honor. The honest test of any operating model is what happens when a venture should be stopped.
In the CVS model, stopping is a scheduled, evidence-based event, not a negotiation. A venture faces a real advance, hold, or stop gate on a fixed cadence. The criteria are agreed in advance: conversion thresholds, retention, signed letters of intent, unit-economics tests. The institution approved those stop criteria up front, which means stopping is not a fight when the moment comes. It is the plan being followed. A venture stopped early at the gate costs under $50,000 (AOS operating model), against the millions an internal project can accrue when nobody can bring themselves to end it.
The operating model pulled off something subtle there. By putting stop criteria in the institution's "approve" column at the start, it made stopping blameless. Nobody has to lose face to end a weak venture, because ending it is the agreed mechanism doing its job, not a person overruling a sponsor.
If you take one thing from this into a vendor conversation, take this. Ask any prospective studio partner for the written split of decision rights before anything is signed, and read it for one thing: does the institution have approval over execution anywhere? If yes, walk it back, because that single blur reintroduces the internal-lab problem you were trying to escape. We put this on the list of demands worth printing on a one-page RFP.
None of this is frictionless in practice, and it would be dishonest to pretend otherwise. A division of rights on paper is necessary but not sufficient. A senior leader will reach for a roadmap decision that is no longer theirs. A studio will occasionally need to escalate something the contract said it owned. The split holds only with active trust and regular maintenance, at the joint board and in the relationship around it. Writing it down is what makes the boundary defensible when it gets tested. It is not what keeps it from being tested.
The model itself is not complicated. You set direction and the bar for stopping. The studio runs the build. A board holds the seam. The whole thing works for one reason: the boundary between those two is drawn sharply, on paper, before the first line of code, and then honored after it.
Nothing here is an offer to sell a security or investment advice.
Field notes on venture building, AI, and capital. No spam, unsubscribe anytime.
By subscribing you agree to receive AOS Insights e-mails. We use your address only for this newsletter - see our Privacy Policy.
